Combined estrogen–progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats

Olatunji, Lawrence Aderemi; Michael, Olugbenga Samuel; Adewumi, Folorunso; Aiyegboyin, I.J.; Olatunji, Victoria A.

doi:10.1016/j.pathophys.2011.09.001

Cited by 21 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported the unfavorable impact of combined oral contraceptive use on cardiometabolic disturbances in both human and experimental animal model [7][8][20][21][22]. Third generation COC which are the currently used hormonal contraceptives was introduced to minimize the metabolic effects associated with the use of the first and second generation COC, however these effects still persist [23,24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ameliorating Effect of Ganoderma lucidum on Combined Oral Contraceptive-induced Cardiometabolic Syndrome in Female Guinea Pigs

Adediji

Adesola

Chris

et al. 2019

AIR

View full text Add to dashboard Cite

Aim: This study evaluated the effect of Ganoderma lucidum on selected biochemical indices for cardiometabolic risk. Study Design: Case-control study. Place and duration of Study: This study was carried out in the Department of Medical Laboratory Science, Babcock University between December, 2018-May, 2019. Methods: The study included 32 female guinea pigs which were assigned into 4 groups (A-D) with 8 in each group. Group A animals served as control, group B animals received only monophasic combined oral contraceptives (COC), group C animals received monophasic COC and 50mg/kg of G. lucidum, group D animals received monophasic COC and 100 mg/kg of G. lucidum. All the test animals received their treatment once daily through oral gavage for 12 weeks. All animals were sacrificed 24 hours after the last dose was given to the test groups. Blood sample was collected via cardiac puncture. Lipoprotein-associated phospholipase-A2 (Lp-PLA2), high sensitive C reactive protein (hsCRP), insulin, insulin-like growth factor-1 (IGF-1), fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) were determined using spectrophotometric methods and ELISA as appropriate. HOMA-IR was calculated using homeostasis model assessment index. Data obtained were statistically analyzed using ANOVA, post hoc, all values were expressed as mean±standard deviation. P value less than 0.05 was considered significant. Results: We observed that groups B (25%) and C (25%) animals had significantly higher levels of hsCRP, LpPLA2, TC, TG, LDL, FBG, IGF-1 and HOMA-IR when compared with groups A (25%) and D animals (25%) (p<0.05), however there was no significant statistical difference when groups B and C were compared. Also we observed higher levels of HDL in groups C and D animals when compared with groups A and B animals but not significant statistically. Conclusion: The use of G. lucidum stymies the development of COC-induced cardiometabolic syndrome in a dose-dependent manner.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The use of combined oral contraceptives (COC), has been associated with increased prevalence of obesity and cardiometabolic disturbances [7,8], increase in body weight has often been stated by women as the major reason for discontinuing the use of COC [9].…”

Section: Introductionmentioning

confidence: 99%

Ameliorating Effect of Ganoderma lucidum on Combined Oral Contraceptive-induced Cardiometabolic Syndrome in Female Guinea Pigs

Adediji

Adesola

Chris

et al. 2019

AIR

View full text Add to dashboard Cite

show abstract

“…(16)(17)(18) Estrogen-associated progestin seems to exert more influence on the increase of insulin resistance, being the oral route more influential than the non-oral route.. (17) Progestin, when administered alone, does not appear to interfere with carbohydrate metabolism. (19) A prospective randomized study including 54 women using oral, transdermal and vaginal hormonal contraceptives showed effects on glucose metabolism, however, regardless of the route of administration. (15) However, in addition to the small sample size, the study was based on an observation time of only nine weeks, which was not sufficient to support the conclusion of the study (Table 02).…”

Section: Carbohydrate Metabolismmentioning

confidence: 99%

“…Studies that did not report the influence of the use of HCCs on carbohydrate metabolism corresponded to large literature revisions, used randomized samples or used a large sample and cross-sectional design. (6,10,(15)(16)(17)(18)(19)(20)(21)(22)(23) A comparative cross-sectional study with 123 women (25 users and 98 controls) showed that there were no differences between groups in fasting blood glucose. (24) A revision conducted by Cochrane evaluated the effect of hormonal contraceptives on carbohydrate metabolism and showed no important differences in different hormonal combinations and routes of administration in women without diabetes.…”

Section: Piltonen Et Almentioning

confidence: 99%

The Use of Combined Hormonal Contraceptives and Occurrence of Metabolic Syndrome: A Narrative Revision

Sousa¹,

Rocha²,

Lima³

et al. 2021

JHS

View full text Add to dashboard Cite

Objective: The goal of this revision is to explain if the use of combined hormonal contraceptives (CHCs) can be correlated to metabolic alterations that may have an association on the occurrence of metabolic syndrome. Methods: Articles published between January 2008 and September 2020 identified in Google Scholar, Scielo, Pubmed, and Cochrane databases were enlisted and narrowed down to 28 selected articles and one Ph.D. thesis. Results: The use of CHCs may influence carbohydrate metabolism, lipid profile, and changes in C-reactive protein (CRP), however, the influence of CHCs on abdominal circumference, blood pressure, and the prevalence of metabolic syndrome is unclear. Conclusions: The results found were controversial in most of the investigated cases of metabolic alterations. Therefore, there is no association between the use of CHCs and the occurrence of metabolic syndrome.

show abstract

“…Glucose (2 g/kg bw) was administered orally (po), and blood glucose was assessed subsequently after 30, 60, 90, and 120 min. Glucose tolerance was expressed as a function of the area under the OGTT curve (AUC) as previously described [24] and post-load glucose responses. IR was determined using the homeostasis model assessment for insulin resistance (HOMA-IR = fasting glucose (mmol/L) × fasting insulin (μU/L)/22.5) whereas HOMA-β (20 × fasting insulin (μU/L)/fasting glucose -3.5) and 1-h post-load glucose levels were used to determine pancreatic β-cell function.…”

Section: Oral Glucose Tolerance Test (Ogtt) Ir and Pancreatic β-Celmentioning

confidence: 99%

Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone

Adeyanju

Olatunji

2019

Journal of Basic and Clinical Physiology and Pharmacology

View full text Add to dashboard Cite

BackgroundCombined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type. COC containing drospirenone (DRSP) is an analog of spironolactone, hence its antimineralocorticoid and antiandrogenic characteristics have been deemed beneficial, although the benefits and/or negative outcome of its usage have not been fully elucidated. We therefore hypothesized that COC with DRSP component will not affect glucose regulation and circulating corticosterone.MethodTen-week-old female Wistar rats were divided into three groups: control (CON), ethinylestradiol/drospirenone COC (EE/DRSP)-treated, and ethinylestradiol/levonorgestrel COC (EE/LN)-treated rats. The treatment lasted for 8 weeks.ResultsResults showed that with the exception of lipid profiles, EE/LN but not EE/DRSP COC treatment affected body weight, glucose tolerance, plasma insulin, corticosterone, (IR), and pancreatic β-cell dysfunction.ConclusionTaken together, the findings showed that the beneficial effect of EE/DRSP could possibly be through the DRSP component. The result also implies that COCs containing DRSP may be a better and safer means of contraception than those with LN with less cardiovascular risks.

show abstract

Combined estrogen–progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats

Cited by 21 publications

References 39 publications

Ameliorating Effect of Ganoderma lucidum on Combined Oral Contraceptive-induced Cardiometabolic Syndrome in Female Guinea Pigs

Ameliorating Effect of Ganoderma lucidum on Combined Oral Contraceptive-induced Cardiometabolic Syndrome in Female Guinea Pigs

The Use of Combined Hormonal Contraceptives and Occurrence of Metabolic Syndrome: A Narrative Revision

Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone

Contact Info

Product

Resources

About